木瓜直播

Meeting Coverage >

TCT

MitraClip for Functional MR: 'It's Never Too Late'

Benefit grows versus meds over time and not hurt by delay in COAPT trial

Paclitaxel Device Scare Highlights PAD Research Flaws

Latest data from the Lutonix research program reassuring, but far from conclusive

EXCEL: Left Main Stenting Holding Up to CABG at 5 Years

The trial held a mortality surprise, though

Mitral Valve Procedure Learning Curve Raises Access Question

And guess which procedures are next for public outcome reporting...

Novel TAVR Valves: Mixed Results in First Head-to-Head Trials

With one a clear loser, another noninferior to existing devices, will operators want to climb the learning curve?

Post-AVR Leaflet Thrombosis Often Vanishes Sans Treatment

Even so, PARTNER 3 substudy found more clinical events with leaflet thickening

Durable-, Bioresorbable-Polymer DES Vie for Short DAPT

Studies explore left main disease, high bleeding risk populations

Patient Data Makes a Slight Dent in Paclitaxel Device Mortality Risk

New meta-analysis still shows risk persists

Dropping Aspirin Early After Stenting Helps High-Risk Patients

TWILIGHT trial has good news for safety

Could Sapien Valve Weather 25 Years With Little Wear?

A billion beats in bench testing say yes

TCT: Lab Study Questions Washing Protocols for Bioprosthetic Heart Valves

Suggests increased leaflet thrombosis risk when storage solutions are rinsed away pre-implant

TCT: Studies Bolster Argument for Protected TAVR

Positive data ahead of CMS reimbursement decision

TCT: Yet More Bad News on Absorb BVS

No advantage in angina and still more risk in further trials

TCT: IVUS Tops Angiography Guidance for Stent Implantation

Intravascular ultrasound-guidance cut TVF in all-comers trial

TCT: Ultrasound Tops RF for Renal Denervation

Head-to-head trial compared techniques for BP effects

TCT: 10 Years On, Surgery for Left Main Disease Edges Stenting

Separate studies suggest some groups do better with CABG

TCT: Near-Infrared Spectroscopy IDs Plaques Likely to Cause Problems

Non-culprit lesions with large lipid core associated with events

TCT: Stopping Antiplatelets 1 Year Post-Stent Risky for Afib Patients?

Underpowered trial suggested oral anticoagulation alone isn't enough

TCT: Denervation May Help Some Pulmonary Hypertension Patients

Pulmonary artery nerve ablation improves outcomes in trial

TCT: TAVR's Prosthesis-Patient Mismatch Problem Gets Airing

It's not just a surgical issue, according to TVT Registry data

TCT: Mitral Valve Device Promising for Milder Functional Cases

Novel transcatheter valve reduced regurgitation versus sham in small trial

TCT: Sapien 3, CoreValve Evolut R on Par for Aortic Stenosis

Head-to-head trial also shows local, general anesthesia outcomes similar

TCT: MitraClip Saves Lives in Functional Mitral Regurgitation

Positive COAPT results may overwrite neutral MITRA-FR findings

TCT: Studies Suggest Thin May Not Always Be in for DES

Resolute Onyx, BioFreedom on par with ultra-thin Orsiro stent

TCT: Femoropopliteal Stents On Par in First Head-to-Head Trial

Primary patency, major adverse events at least as good with Eluvia as Zilver PTX

TCT: Orsiro Stent has Its Day in BIOFLOW V Trial

Does this mean superiority over Xience?

TCT: Spotlight on Novel Heart Tech

Polymer valves, leaflet laceration, and more could help solve some persistent problems in valve procedures

TCT: Second Chance for MitraClip in Functional Mitral Regurgitation?

COAPT takes the spotlight in San Diego

TCT: Stent No Better Than Sham for Stable Angina in ORBITA

No symptom relief beyond placebo effect in first sham-controlled trial

TCT: Are Disappearing-Polymer Metallic DES the Way to Shorter DAPT Duration?

Trials show good results with two such stents

TCT: 6-Month DAPT OK After STEMI With Modern DES

Non-inferior outcomes versus typical 12-month regimen in DAPT-STEMI

TCT: FDA Reiterates Caution on Absorb Stent

Agency cites ongoing risk at 3-plus years after presumed reabsorption

TCT: Easier Recovery with PCI vs CABG Validated in EXCEL Trial

But early quality of life advantage largely dissipates by 1 year

TCT: Complex Bifurcation Stenting Approach Bests Provisional Stenting

Double kissing crush technique cut target lesion failure and thrombosis

TCT: Multivessel PCI Not Best in Cardiogenic Shock

Trial data show mortality disadvantage versus treating culprit lesions only

TCT: Orsiro No Better Than EES for CTO

Also, injectable collagenase eases PCI for CTO in trial

TCT: Amulet LAA Occluder Hot on the Heels of Watchman

Another LAA closure device shows favorable results in trial

TCT: Novel Drug-Coated Balloon Promising for Periphery

Stellarex beat angioplasty alone in fairly complex PAD population trial

Aneurysm Sealing Device Hits Hurdles

Migration, endoleaks, and aneurysm growth cited for novel Nellix device

TCT: TAVR Holds Up Pretty Well Over Time

Also, 2-year data confirm lasting improvements in QoL

2